Companion Diagnostic

One of the keys to diagnosing and treating Glioblastoma is having a full picture of the disease. Knowing which of the four GBM subtypes each patient has is a key piece of the puzzle. Some subtypes react differently to certain therapies, and can even change subtypes in response to a therapy, meaning the treatment or approach may need to change to stay ahead of the cancer.

Ultimately, our goal is to provide physicians and life science companies with clear information about each GBM's subtype, to enable them to make the best decisions possible.

There are over 150 different companies developing treatments for GBM.

Any company would benefit from using a diagnostic test designed to identify which of the four subtypes they can improve outcomes the most.

There are over 150 different companies developing treatments for GBM.Any company would benefit from using a diagnostic test designed to identify which of the four subtypes they can improve outcomes the most.

There are over 150 different companies developing treatments for GBM.

Any company would benefit from using a diagnostic test designed to identify which of the four subtypes they can improve outcomes the most.